Medicine in development
Amyotrophic lateral sclerosis
The masitinib clinical programme
Key information about the masitinib program, presented in a simple and accessible way.
CURRENT STATUS
Phase 3
Preclinical
Phase 1
Phase 2
Phase 3
01
HOW MASITINIB ACTS ON THE DISEASE
Regulating the immune system’s “clean-up” process
A normal number of mast cells and/or microglia allows the waste resulting from the activity of our immune system to be properly cleared.
An abnormally high number of mast cells and/or microglia prevents the waste resulting from the activity of our immune system from being properly cleared… and creates disorder: inflammation spreads throughout the system, like dust building up when the cleaning is no longer done.
Masitinib targets mast cells and microglia. The hypothesis under evaluation in phase 3 is that, by reducing the excess of these cells, it slows disease progression.
02
THE PROGRAM AT A GLANCE
Key study information
Four key figures to understand the development stage, protocol duration and potential of the masitinib program in amyotrophic lateral sclerosis.
Current stage
Phase 3
Clinical program
Duration of treatment assessed
48
weeks
Eligible patients
50,000
in Europe and the United States
Market size
~€2.5bn
reported estimate
03
EXPLORE FURTHER